Chapel Hill, NC, United States of America

Mary Beth Thomas


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mary Beth Thomas: Innovator in Cell Death Research

Introduction

Mary Beth Thomas is a prominent inventor based in Chapel Hill, NC (US). She has made significant contributions to the field of neuroscience, particularly in the diagnosis and treatment of conditions involving cell death. Her innovative work has the potential to impact various neurological and psychiatric disorders.

Latest Patents

Mary Beth Thomas holds a patent for "Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death." This invention relates to protective nucleic acids that can prevent, delay, or rescue cells from death. The patent encompasses various aspects, including nucleic acids of the protective sequence, host cell expression systems, and transgenic animals. It also covers methods for diagnosing and treating conditions associated with cell death, particularly those affecting the central and peripheral nervous systems.

Career Highlights

Mary Beth Thomas is affiliated with Cogent Neuroscience, Inc., where she continues her research and development efforts. Her work focuses on creating therapeutic agents that can modulate the expression and activity of protective sequences involved in cell death. This research is crucial for developing treatments for various conditions that can lead to cell death.

Collaborations

Some of her notable coworkers include Donald C Lo and Shawn Barney. Their collaborative efforts contribute to advancing the understanding and treatment of cell death-related disorders.

Conclusion

Mary Beth Thomas is a trailblazer in the field of neuroscience, with her innovative patent addressing critical issues related to cell death. Her work at Cogent Neuroscience, Inc. and collaborations with esteemed colleagues highlight her commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…